|
1
|
Delebinski CI, Georgi S, Kleinsimon S,
Twardziok M, Kopp B, Melzig MF and Seifert G: Analysis of
proliferation and apoptotic induction by 20 steroid glycosides in
143B osteosarcoma cells in vitro. Cell Prolif. 48:600–610. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu SY, Deng SY, He YB and Ni GX: miR-451
inhibits cell growth, migration and angiogenesis in human
osteosarcoma via down-regulating IL 6R. Biochem Biophys Res Commun.
482:987–993. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang J, Hou W, Chai M, Zhao H, Jia J, Sun
X, Zhao B and Wang R: MicroRNA-127-3p inhibits proliferation and
invasion by targeting SETD8 in human osteosarcoma cells. Biochem
Biophys Res Commun. 469:1006–1011. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Isakoff MS, Bielack SS, Meltzer P and
Gorlick R: Osteosarcoma: Current treatment and a collaborative
pathway to success. J Clin Oncol. 33:3029–3035. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao JZ, Chen FH, Wang L, Wei H and Meng
SL: YM155 inhibits tumor growth and enhances chemosensitivity to
cisplatin in osteosarcoma. Eur Rev Med Pharmacol Sci. 19:2062–2069.
2015.PubMed/NCBI
|
|
6
|
Brown HK, Tellez-Gabriel M and Heymann D:
Cancer stem cells in osteosarcoma. Cancer Lett. 386:189–195. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wise R, Andrews JM and Danks G: In-vitro
activity of enoxacin (CL-919), a new quinoline derivative, compared
with that of other antimicrobial agents. J Antimicrob Chemother.
13:237–244. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cao S, Sun R, Wang W, Meng X, Zhang Y,
Zhang N and Yang S: RNA helicase DHX9 may be a therapeutic target
in lung cancer and inhibited by enoxacin. Am J Transl Res.
9:674–682. 2017.PubMed/NCBI
|
|
9
|
Mondal ER, Das SK and Mukherjee P:
Comparative evaluation of antiproliferative activity and induction
of apoptosis by some fluoroquinolones with a human non-small cell
lung cancer cell line in culture. Asian Pac J Cancer Prev.
5:196–204. 2004.PubMed/NCBI
|
|
10
|
Sousa E, Graça I, Baptista T, Vieira FQ,
Palmeira C, Henrique R and Jerónimo C: Enoxacin inhibits growth of
prostate cancer cells and effectively restores microRNA processing.
Epigenetics. 8:548–558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Melo S, Villanueva A, Moutinho C, Davalos
V, Spizzo R, Ivan C, Rossi S, Setien F, Casanovas O, Simo-Riudalbas
L, et al: Small molecule enoxacin is a cancer-specific growth
inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated
microRNA processing. Proc Natl Acad Sci USA. 108:4394–4399. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhanot SK, Singh M and Chatterjee NR: The
chemical and biological aspects of fluoroquinolones: Reality and
dreams. Curr Pharm Des. 7:311–335. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sampo M, Koivikko M, Taskinen M, Kallio P,
Kivioja A, Tarkkanen M and Böhling T: Incidence, epidemiology and
treatment results of osteosarcoma in Finland-a nationwide
population-based study. Acta Oncol. 50:1206–1214. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mirabello L, Troisi RJ and Savage SA:
International osteosarcoma incidence patterns in children and
adolescents, middle ages and elderly persons. Int J Cancer.
125:229–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dai X, Ma W, He X and Jha RK: Review of
therapeutic strategies for osteosarcoma, chondrosarcoma, and
Ewing's sarcoma. Med Sci Monit. 17:RA177–RA190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ando K, Heymann MF, Stresing V, Mori K,
Rèdini F and Heymann D: Current therapeutic strategies and novel
approaches in osteosarcoma. Cancers (Basel). 5:591–616. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lamoureux F, Trichet V, Chipoy C,
Blanchard F, Gouin F and Redini F: Recent advances in the
management of osteosarcoma and forthcoming therapeutic strategies.
Expert Rev Anticancer Ther. 7:169–181. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Picci P: Osteosarcoma (osteogenic
sarcoma). Orphanet J Rare Dis. 2:62007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Liao Q, Li K, Zhong D, Weng X and Mi
M: Knockdown of endothelin A receptor expression inhibits
osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse
model. Mol Med Rep. 5:1391–1395. 2012.PubMed/NCBI
|
|
20
|
Kato H, Wakabayashi H, Naito Y, Kato S,
Nakagawa T, Matsumine A and Sudo A: Anti-tumor necrosis factor
therapy inhibits lung metastasis in an osteosarcoma cell line.
Oncology. 88:139–146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Meazza C and Scanagatta P: Metastatic
osteosarcoma: A challenging multidisciplinary treatment. Expert Rev
Anticancer Ther. 16:543–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shay G, Lynch CC and Fingleton B: Moving
targets: Emerging roles for MMPs in cancer progression and
metastasis. Matrix Biol. 44-46:200–206. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jabłońska-Trypuć A, Matejczyk M and
Rosochacki S: Matrix metalloproteinases (MMPs), the main
extracellular matrix (ECM) enzymes in collagen degradation, as a
target for anticancer drugs. J Enzyme Inhib Med Chem. 31 (Suppl
1):S177–S183. 2016. View Article : Google Scholar
|
|
24
|
Zhu KP, Ma XL and Zhang CL: LncRNA ODRUL
contributes to osteosarcoma progression through the miR-3182/MMP2
Axis. Mol Ther. 25:2383–2393. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qiu R, Li X, Qin K, Chen X, Wang R, Dai Y,
Deng L and Ye Y: Antimetastatic effects of calycosin on
osteosarcoma and the underlying mechanism. Biofactors. 45:975–982.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li J, Yang Z, Li Y, Xia J, Li D, Li H, Ren
M, Liao Y, Yu S, Chen Y, et al: Cell apoptosis, autophagy and
necroptosis in osteosarcoma treatment. Oncotarget. 7:44763–44778.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Silvestris F, Ribatti D, Nico B,
Silvestris N, Romito A and Dammacco F: Apoptosis or programmed cell
death: Regulatory and pathophysiological mechanisms. Ann Ital Med
Int. 10:7–13. 1995.(In Italian). PubMed/NCBI
|
|
28
|
Cardenas C, Montagna MK, Pitruzzello M,
Lima E, Mor G and Alvero AB: Adipocyte microenvironment promotes
Bclxl expression and confers chemoresistance in ovarian
cancer cells. Apoptosis. 22:558–569. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Park SS, Lee DM, Lim JH, Lee D, Park SJ,
Kim HM, Sohn S, Yoon G, Eom YW, Jeong SY, et al: Pyrrolidine
dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to
doxorubicin by inducing paraptosis. Carcinogenesis. 39:458–470.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Committee on Infectious Diseases: The use
of systemic fluoroquinolones. Pediatrics. 118:1287–1292. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hampel B, Hullmann R and Schmidt H:
Ciprofloxacin in pediatrics: Worldwide clinical experience based on
compassionate use-safety report. Pediatr Infect Dis J. 16:127–129,
160-162. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bacci C, Galli L, de Martino M and
Chiappini E: Fluoroquinolones in children: Update of the
literature. J Chemother. 27:257–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Huvos AG: Osteogenic sarcoma of bones and
soft tissues in older persons. A clinicopathologic analysis of 117
patients older than 60 years. Cancer. 57:1442–1449. 1986.
View Article : Google Scholar : PubMed/NCBI
|
